CORT
CORCEPT THERAPEUTICS INC
$82.91
-0.41%
$8.9B
No data for this timeframe.
Vol
Market Cap$8.9B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders50 funds
Inst. Value$2.0B
Inst. Activity12 buys / 23 sells
Insider Activity1B / 11S
Insider Net $-$13.6M
Reddit Sentiment50° Neutral
SEC Reports12
Recent Activity
Jun 4, 2026
SEC
Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a total of $6.91M in ope
CLUSTER — Impact 3/10
Jun 3, 2026
SEC
Four CORT insiders — including the CEO, CFO, and two senior executives — sold a total of $5.50M in open-market shares wi
CLUSTER — Impact 3/10
Jun 3, 2026
SEC
Four Corcept Therapeutics insiders, including the CEO, CFO, and two other senior executives, sold a total of $5.50M in o
CLUSTER — Impact 5/10
Jun 2, 2026
Insider
Guyer William sold 20,000 shares
Chief Development Officer @ $70.60 ($1.4M)
Jun 2, 2026
Insider
Guyer William acquired via exercise 20,000 shares
Chief Development Officer @ $21.65 ($433.0K)
Jun 2, 2026
Insider
Lyon Joseph Douglas surrendered for taxes 269 shares
See Remarks @ $70.44 ($18.9K)
Inst.
FMR LLC — ADD
3,190,192 shares ($128.6M)
Inst.
FIRST TRUST ADVISORS LP — DOUBLED
2,173,376 shares ($87.6M)
Price Targets
$88.00
+6.1% upside
Buy
Current $82.91
Low $50.00
Median $88.00
High $135.00
5 analysts
$50.00
$135.00
Analyst Ratings
2Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 13, 2026 | UBS | UPGRADE | Neutral → Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 1, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.04 ▼ -29.5% | $0.02 — $0.06 | -87% YoY | 3 |
| Next Q | $0.25 ▲ +56.4% | $0.14 — $0.34 | 58% YoY | 3 |
| Current FY | $0.49 ▲ +20.1% | $0.17 — $0.80 | -41% YoY | 4 |
| Next FY | $2.50 ▲ +55.2% | $0.32 — $5.38 | 412% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a total of $6.91M in ope
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Four CORT insiders — including the CEO, CFO, and two senior executives — sold a total of $5.50M in open-market shares wi
Jun 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $489.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $229.1M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $194.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $164.4M | — |
| STATE STREET CORP | $129.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Guyer William | SELL | $1.4M |
| Jun 2, 2026 | Guyer William | M | $433.0K |
| Jun 2, 2026 | Lyon Joseph | F | $18.9K |
| Jun 2, 2026 | Maduck Sean | F | $31.8K |
| Jun 2, 2026 | Mokari Atabak | F | $27.8K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $2.0B total value (50,080,477 shares) as of 2026-Q1. Top holders: BlackRock,, RENAISSANCE, VANGUARD. Net selling activity: 23 institutions trimmed/exited vs 12 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 12,151,276 | $489.8M | 24.3% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 5,682,783 | $229.1M | 11.3% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,820,568 | $194.3M | 9.6% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4,077,196 | $164.4M | 8.1% | — |
| 5 | STATE STREET CORP | 3,200,946 | $129.0M | 6.4% | — |
| 6 | FMR LLC | 3,190,192 | $128.6M | 6.4% | ADD +32.1% |
| 7 | FIRST TRUST ADVISORS LP | 2,173,376 | $87.6M | 4.3% | DOUBLED +213.5% |
| 8 | DIMENSIONAL FUND ADVISORS LP | 1,553,135 | $62.6M | 3.1% | — |
| 9 | D. E. Shaw & Co., Inc. | 1,181,348 | $47.6M | 2.4% | TRIM -71.0% |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,119,959 | $45.1M | 2.2% | — |
| 11 | MORGAN STANLEY | 1,018,845 | $41.1M | 2.0% | TRIM -36.0% |
| 12 | TWO SIGMA INVESTMENTS, LP | 945,884 | $38.1M | 1.9% | — |
| 13 | Cerity Partners LLC | 731,689 | $29.5M | 1.5% | — |
| 14 | GOLDMAN SACHS GROUP INC | 725,822 | $29.3M | 1.4% | — |
| 15 | Invesco Ltd. | 628,384 | $25.3M | 1.3% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 590,307 | $23.8M | 1.2% | — |
| 17 | Boston Trust Walden Corp | 462,606 | $18.6M | 0.9% | — |
| 18 | CITIGROUP INC | 421,067 | $17.0M | 0.8% | — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 345,000 | $13.9M | 0.7% | — |
| 20 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 334,875 | $13.5M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 2,414,640 | 3,190,192 | +32.1% | $128.6M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 693,317 | 2,173,376 | +213.5% | $87.6M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 1,592,059 | 1,018,845 | -36.0% | $41.1M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | DOUBLED | 124,400 | 324,901 | +161.2% | $13.1M | 2026-Q1 |
| FRANKLIN RESOURCES INC | TRIM | 468,178 | 305,211 | -34.8% | $12.3M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | TRIM | 507,967 | 214,572 | -57.8% | $9.0M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 411,170 | 212,074 | -48.4% | $8.5M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 76,417 | 194,041 | +153.9% | $7.8M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | ADD | 97,660 | 126,429 | +29.5% | $5.1M | 2026-Q1 |
| Rockefeller Capital Management L.P. | TRIM | 186,631 | 123,497 | -33.8% | $5.0M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 221,444 | 117,954 | -46.7% | $4.8M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 83,658 | 111,736 | +33.6% | $4.5M | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 42,654 | 75,474 | +76.9% | $3.0M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 149,845 | 67,972 | -54.6% | $2.7M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 3,794 | 37,242 | +881.6% | $1.5M | 2026-Q1 |
| SEI INVESTMENTS CO | TRIM | 94,756 | 32,379 | -65.8% | $1.3M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 7,068 | 25,916 | +266.7% | $1.0M | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | DOUBLED | 9,422 | 23,795 | +152.5% | $959.2K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 9,532 | 16,044 | +68.3% | $646.7K | 2026-Q1 |
| Russell Investments Group, Ltd. | NEAR_EXIT | 57,618 | 13,128 | -77.2% | $521.6K | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 19,489 | 9,548 | -51.0% | $384.9K | 2026-Q1 |
| M&T BANK CORP | TRIM | 13,240 | 8,459 | -36.1% | $341.0K | 2026-Q1 |
| Concurrent Investment Advisors, LLC | TRIM | 13,845 | 8,100 | -41.5% | $326.5K | 2026-Q1 |
| Neuberger Berman Group LLC | NEAR_EXIT | 181,964 | 6,895 | -96.2% | $277.9K | 2026-Q1 |
| Mariner, LLC | TRIM | 19,765 | 6,006 | -69.6% | $242.2K | 2026-Q1 |
13 unique insiders with 50 transactions. Net insider value: -$13.6M ($2.5M bought, $16.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Guyer William | Chief Development Officer | SELL | 20,000 | $70.60 | $1.4M |
| Jun 2, 2026 | Guyer William | Chief Development Officer | EXERCISE | 20,000 | $21.65 | $433.0K |
| Jun 2, 2026 | Lyon Joseph Douglas | See Remarks | TAX W/H | 269 | $70.44 | $18.9K |
| Jun 2, 2026 | Maduck Sean | See Remarks | TAX W/H | 452 | $70.44 | $31.8K |
| Jun 2, 2026 | Mokari Atabak | Chief Financial Officer | TAX W/H | 395 | $70.44 | $27.8K |
| Jun 2, 2026 | Robb Gary Charles | Chief Business Officer | TAX W/H | 358 | $70.44 | $25.2K |
| Jun 1, 2026 | Lyon Joseph Douglas | See Remarks | AWARD | 537 | $70.44 | $37.8K |
| Jun 1, 2026 | Guyer William | Chief Development Officer | AWARD | 877 | $70.44 | $61.8K |
| Jun 1, 2026 | Maduck Sean | See Remarks | AWARD | 615 | $70.44 | $43.3K |
| Jun 1, 2026 | Maduck Sean | See Remarks | SELL | 21,069 | $70.11 | $1.5M |
| Jun 1, 2026 | Maduck Sean | See Remarks | EXERCISE | 25,000 | $8.27 | $206.8K |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | AWARD | 634 | $70.44 | $44.7K |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | SELL | 40,000 | $70.00 | $2.8M |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | EXERCISE | 40,000 | $19.26 | $770.4K |
| Jun 1, 2026 | Robb Gary Charles | Chief Business Officer | AWARD | 776 | $70.44 | $54.7K |
| Jun 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | SELL | 12,837 | $69.74 | $895.3K |
| May 29, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | GIFT | 300,000 | — | — |
| May 27, 2026 | WILSON JAMES N | Director | GIFT | 892,056 | — | — |
| May 27, 2026 | Maduck Sean | See Remarks | EXERCISE | 75,000 | $8.27 | $620.3K |
| May 27, 2026 | Maduck Sean | See Remarks | SELL | 54,575 | $65.37 | $3.6M |
| May 27, 2026 | Lyon Joseph Douglas | See Remarks | SELL | 5,000 | $65.00 | $325.0K |
| May 21, 2026 | Park Kimberly | Director | AWARD | 12,500 | — | — |
| May 21, 2026 | MAHONEY DAVID L | Director | AWARD | 12,500 | — | — |
| May 21, 2026 | Murray Joshua M. | Director | AWARD | 12,500 | — | — |
| May 21, 2026 | Swisher Daniel N JR | Director | AWARD | 12,500 | — | — |
| May 21, 2026 | WILSON JAMES N | Director | AWARD | 12,500 | — | — |
| May 21, 2026 | BAKER G LEONARD JR | Director | AWARD | 12,500 | — | — |
| May 21, 2026 | Alton Gregg H | Director | AWARD | 12,500 | — | — |
| May 13, 2026 | Robb Gary Charles | Chief Business Officer | GIFT | 5,300 | — | — |
| May 5, 2026 | Guyer William | Chief Development Officer | SELL | 20,000 | $51.83 | $1.0M |
| May 5, 2026 | Guyer William | Chief Development Officer | EXERCISE | 20,000 | $21.65 | $433.0K |
| May 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | SELL | 40,000 | $50.10 | $2.0M |
| Apr 22, 2026 | WILSON JAMES N | Director | GIFT | 2,000 | — | — |
| Apr 7, 2026 | Guyer William | Chief Development Officer | EXERCISE | 20,000 | $21.65 | $433.0K |
| Apr 7, 2026 | Guyer William | Chief Development Officer | SELL | 20,000 | $40.97 | $819.4K |
| Apr 6, 2026 | WILSON JAMES N | Director | GIFT | 5,000 | — | — |
| Mar 25, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | SELL | 26,198 | $50.07 | $1.3M |
| Mar 20, 2026 | WILSON JAMES N | Director | GIFT | 4,000 | — | — |
| Mar 20, 2026 | Guyer William | Chief Development Officer | EXERCISE | 11,767 | $21.65 | $254.8K |
| Mar 20, 2026 | Guyer William | Chief Development Officer | SELL | 11,767 | $36.01 | $423.7K |
| Mar 17, 2026 | BAKER G LEONARD JR | Director | BUY | 75,782 | $33.00 | $2.5M |
| Mar 13, 2026 | MAHONEY DAVID L | Director | EXERCISE | 30,000 | $5.86 | $175.8K |
| Mar 13, 2026 | MAHONEY DAVID L | Director | TAX W/H | 5,469 | $32.15 | $175.8K |
| Mar 13, 2026 | MAHONEY DAVID L | Director | GIFT | 24,531 | — | — |
| Mar 13, 2026 | MAHONEY DAVID L | Director | J | 24,531 | — | — |
| Mar 13, 2026 | WILSON JAMES N | Director | GIFT | 28,000 | — | — |
| Mar 4, 2026 | Guyer William | Chief Development Officer | EXERCISE | 8,233 | $21.65 | $178.2K |
| Mar 3, 2026 | Lyon Joseph Douglas | See Remarks | TAX W/H | 89 | $35.97 | $3.2K |
| Mar 3, 2026 | Robb Gary Charles | Chief Business Officer | TAX W/H | 121 | $35.97 | $4.4K |
| Mar 3, 2026 | Maduck Sean | See Remarks | TAX W/H | 110 | $35.97 | $4.0K |
12 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 9 neutral. Avg impact: 3.9/10.
NEUTRAL
CLUSTER
3/10
Five Corcept Therapeutics insiders, including the CEO, CFO, and Chief Development Officer, sold a to
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Four CORT insiders — including the CEO, CFO, and two senior executives — sold a total of $5.50M in o
Jun 3, 2026
BEARISH
CLUSTER
5/10
Four Corcept Therapeutics insiders, including the CEO, CFO, and two other senior executives, sold a
Jun 3, 2026
NEUTRAL
CLUSTER
4/10
Three top executives at Corcept Therapeutics (CEO, CFO, and a senior officer) sold a total of $7.59M
Jun 3, 2026
NEUTRAL
CLUSTER
3/10
CEO Joseph Belanoff sold $895K worth of CORT shares on June 1, and two other executives sold a combi
Jun 3, 2026
BULLISH
8-K
6/10
Corcept disclosed that the DOJ, California Department of Insurance, and named Plaintiff States have
Jun 3, 2026
NEUTRAL
CLUSTER
3/10
Two Corcept Therapeutics insiders sold a combined $3.89M in open-market sales on May 27, 2026, with
Jun 2, 2026
NEUTRAL
CLUSTER
3/10
Two Corcept Therapeutics insiders sold a total of ~$3.9M in open-market shares on May 27, 2026, whil
May 29, 2026
NEUTRAL
CLUSTER
3/10
Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings
May 7, 2026
NEUTRAL
CLUSTER
3/10
Corcept Therapeutics CEO Joseph Belanoff sold $1.31M worth of shares in a single open-market transac
Mar 27, 2026
NEUTRAL
CLUSTER
4/10
Chief Development Officer William Guyer exercised stock options and sold 11,767 shares in the open m
Mar 24, 2026
BULLISH
8-K
7/10
Corcept Therapeutics reported full-year 2025 revenue of $761.4 million, a 12.8% increase from 2024,
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 2 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$88.00 mean target
+6.1% upside
Buy (1.50)
$50.00 Low
$135.00 High
| Metric | Value |
|---|---|
| Current Price | $82.91 |
| Target Low | $50.00 |
| Target Mean | $88.00 |
| Target Median | $88.00 |
| Target High | $135.00 |
| # Analysts | 5 |
| Recommendation | Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.04 | $0.02 | $0.06 | -87.4% | -29.5% | 1↑ 2↓ | $0.2B | 14.3% | 3 |
| Next Q 2026-09-30 |
$0.25 | $0.14 | $0.34 | 58.3% | +56.4% | 2↑ 1↓ | $0.3B | 28.4% | 3 |
| Current FY 2026-12-31 |
$0.49 | $0.17 | $0.80 | -40.6% | +20.1% | 2↑ 1↓ | $1.0B | 29.8% | 4 |
| Next FY 2027-12-31 |
$2.50 | $0.32 | $5.38 | 411.8% | +55.2% | 2↑ 1↓ | $1.4B | 41.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.037 | |
| 7d ago | $0.037 | |
| 30d ago | $0.052 | -0.015 |
| 60d ago | $0.052 | -0.015 |
| 90d ago | $0.028 | +0.009 |
5 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 13, 2026 | UBS | UPGRADE | Neutral | Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 1, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 26, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Wolfe Research | UPGRADE | Underperform | Peer Perform |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | UBS | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 7 | 3 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 7 | 2 | 0 | 1 | 75% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 1 | 75% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 1 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
CASE STUDY CORT
▲ 1
💬 0
⚡ 0.5
Jul 11, 2026
fda_pdufa
PDUFA: CORT — relacorilant in platinum-resistant ovarian cancer — 2026-07-11
FDA target action date 2026-07-11 for CORT (CORCEPT THERAPEUTICS INC). Drug: relacorilant. Indication: platinum-resistant ovarian cancer. PDUFA target
Jun 10, 2026
short_volume
Short Volume: CORT — 86.4% short (0.5M / 0.6M)
Short: 492,401 | Exempt: 4,159 | TRF Vol: 569,713 | Short Ratio: 86.4% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
Clinical Trial
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Miricorilant (Cohort A) (Phase 2)
Trial: A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis
May 27, 2026
short_volume
Short Volume: CORT — 74.7% short (0.6M / 0.8M)
Short: 570,622 | Exempt: 11,128 | TRF Vol: 764,205 | Short Ratio: 74.7% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CORT — 86.6% short (0.5M / 0.6M)
Short: 534,051 | Exempt: 3,237 | TRF Vol: 616,568 | Short Ratio: 86.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: CORT — 1.2M shares, 29,064 trades
Week starting 2026-05-18. Total ATS volume: 1,178,996 shares across 29,064 trades.
May 16, 2026
Clinical Trial
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase Phase 2 — TERMINATED
May 14, 2026
short_volume
Short Volume: CORT — 83.5% short (0.6M / 0.7M)
Short: 562,804 | Exempt: 1,826 | TRF Vol: 673,707 | Short Ratio: 83.5% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: CORT — 2.1M shares, 40,445 trades
Week starting 2026-05-11. Total ATS volume: 2,053,057 shares across 40,445 trades.
May 4, 2026
dark_pool
Dark Pool: CORT — 1.4M shares, 31,628 trades
Week starting 2026-05-04. Total ATS volume: 1,427,344 shares across 31,628 trades.
May 1, 2026
short_interest
FTD: CORT — 99,904 shares ($4.6M) failed to deliver
Settlement: 20260501, Price: $46.52, FTD Value: $4,647,534.08, CORCEPT THERAPEUTICS INCORPORA
May 1, 2026
short_volume
Short Volume: CORT — 71.7% short (0.8M / 1.2M)
Short: 842,516 | Exempt: 100 | TRF Vol: 1,174,740 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
CORT Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
dark_pool
Dark Pool: CORT — 2.1M shares, 51,005 trades
Week starting 2026-04-27. Total ATS volume: 2,116,844 shares across 51,005 trades.
Apr 20, 2026
dark_pool
Dark Pool: CORT — 1.2M shares, 25,017 trades
Week starting 2026-04-20. Total ATS volume: 1,198,432 shares across 25,017 trades.
Apr 13, 2026
dark_pool
Dark Pool: CORT — 1.3M shares, 29,147 trades
Week starting 2026-04-13. Total ATS volume: 1,289,082 shares across 29,147 trades.
Mar 25, 2026
FDA
LIFYORLITM
Original Approval — Type 1 - New Molecular Entity — RELACORILANT — CAPSULE — ORAL
Feb 23, 2026
Clinical Trial
A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas
Phase Phase 2 — TERMINATED